Certain Biologic Medicines for Psoriasis Appears to Reduce Cardiometabolic Risk, Study Suggests

A study has suggested that in the treatment of patients with psoriasis, usage of certain biologic medicines appears to reduce aortic vascular inflammation and cardiometabolic risk biomarkers, including C-reactive protein (CRP) and interleukin (IL)-6.

Photo: Biologic Medicines for Psoriasis | InStyleHealth


Experts conducted a meta-analysis of studies investigating the efficacy of licensed biologic therapies on imaging and biomarkers of cardiovascular disease risk in patients with psoriasis. From the five studies included in the final examination, 2 were retained for the meta-analysis.

Comparing with placebo, adalimumab showed no significant benefit for aortic vascular inflammation at weeks 12-16. Similarly, both adalimumab and secukinumab conferred no beneficial effect on imaging biomarkers (aortic vascular inflammation or flow mediated dilatation) relative to placebo. Ustekinumab was the only exception which yielded a reduction in aortic vascular inflammation at week 12 but not at week 52 after the open-label extension period.

Concurrently, the strongest reduction in blood-based cardiometabolic risk biomarkers was seen with adalimumab and phototherapy when compared with placebo.

Surrogate marker findings revealed that ustekinumab lowers aortic vascular inflammation, while tumor necrosis factor inhibitor and phototherapy induce CRP and IL-6 reduction. Additional randomized controlled trials assessing cardiovascular events are warranted to inform clinical practice according to researchers.

 

Source: J Invest Dermatol 2021; doi:10.1016/j.jid.2021.03.024


If you have any suggestions, please let us know.

Post a Comment (0)
Previous Post Next Post